Buy Or Sell Opportunity • Jun 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to €17.00. The fair value is estimated to be €21.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. New Risk • May 28
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Price Target Changed • May 26
Price target decreased by 8.6% to €25.40 Down from €27.80, the current price target is an average from 5 analysts. New target price is 51% above last closing price of €16.86. Stock is down 38% over the past year. The company is forecast to post earnings per share of €1.03 next year compared to a net loss per share of €0.02 last year. Declared Dividend • May 20
Dividend of €0.60 announced Dividend of €0.60 is the same as last year. Ex-date: 24th June 2026 Payment date: 26th June 2026 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (71% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Duyuru • May 12
Stratec SE, Annual General Meeting, Jun 23, 2026 Stratec SE, Annual General Meeting, Jun 23, 2026, at 13:00 W. Europe Standard Time. Duyuru • Apr 29
Stratec SE announces Annual dividend, payable on June 26, 2026 Stratec SE announced Annual dividend of EUR 0.6000 per share payable on June 26, 2026, ex-date on June 24, 2026 and record date on June 25, 2026. Price Target Changed • Aug 22
Price target decreased by 7.9% to €37.32 Down from €40.50, the current price target is an average from 6 analysts. New target price is 44% above last closing price of €26.00. Stock is down 41% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €1.32 last year. Reported Earnings • Aug 19
First half 2025 earnings released: EPS: €0.21 (vs €0.32 in 1H 2024) First half 2025 results: EPS: €0.21 (down from €0.32 in 1H 2024). Revenue: €118.6m (flat on 1H 2024). Net income: €2.60m (down 34% from 1H 2024). Profit margin: 2.2% (down from 3.3% in 1H 2024). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year whereas the company’s share price has fallen by 32% per year. Duyuru • Jun 30
Stratec Se Approves the Dividend, Payable on July 2, 2025 Stratec SE at its Annual General Meeting held on June 27, 2025, the company will enable its shareholders to participate in the company’s performance by distributing a dividend of €0.60 per share for the past 2024 financial year (previous year’s dividend: €0.55 per share). The distribution total amounts to €7.3 million and will be paid to shareholders via their depositing banks on July 2, 2025. Duyuru • May 31
Stratec SE Confirms Consolidated Earnings Guidance for the Year 2025 Stratec SE confirmed consolidated earnings guidance for the year 2025. Consolidated sales at constant currency expected to show growth in a low to medium single-digit percentage range Here, earnings contributions from Development and Services are expected to show significant intra-year growth in the fourth quarter of 2025 in particular. Duyuru • May 21
Stratec SE, Annual General Meeting, Jun 27, 2025 Stratec SE, Annual General Meeting, Jun 27, 2025, at 14:00 W. Europe Standard Time. Duyuru • May 20
Stratec SE announces Annual dividend, payable on July 02, 2025 Stratec SE announced Annual dividend of EUR 0.6000 per share payable on July 02, 2025, ex-date on June 30, 2025 and record date on July 01, 2025. Duyuru • May 09
Stratec SE(XTRA:SBS) dropped from Germany SDAX (Total Return) Index Stratec SE has been dropped from the Germany SDAX (Total Return) Index Duyuru • May 07
Stratec SE to Report Q1, 2025 Final Results on May 30, 2025 Stratec SE announced that they will report Q1, 2025 final results on May 30, 2025 Duyuru • Dec 06
Stratec SE to Report Fiscal Year 2024 Results on Mar 27, 2025 Stratec SE announced that they will report fiscal year 2024 results on Mar 27, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: €0.045 (vs €0.42 in 3Q 2023) Third quarter 2024 results: EPS: €0.045 (down from €0.42 in 3Q 2023). Revenue: €57.2m (down 8.7% from 3Q 2023). Net income: €549.0k (down 89% from 3Q 2023). Profit margin: 1.0% (down from 8.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. New Risk • Sep 27
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 53% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 11
Second quarter 2024 earnings released: EPS: €0.29 (vs €0.086 in 2Q 2023) Second quarter 2024 results: EPS: €0.29 (up from €0.086 in 2Q 2023). Revenue: €68.2m (up 5.7% from 2Q 2023). Net income: €3.48m (up 233% from 2Q 2023). Profit margin: 5.1% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 13
Upcoming dividend of €0.55 per share Eligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 55% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.8%). New Risk • Apr 30
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 11% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Minor Risk Profit margins are more than 30% lower than last year (4.8% net profit margin). Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: €0.037 (vs €0.11 in 1Q 2023) First quarter 2024 results: EPS: €0.037 (down from €0.11 in 1Q 2023). Revenue: €50.9m (down 16% from 1Q 2023). Net income: €447.0k (down 67% from 1Q 2023). Profit margin: 0.9% (down from 2.3% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Price Target Changed • Apr 02
Price target decreased by 13% to €45.50 Down from €52.17, the current price target is an average from 6 analysts. New target price is 16% above last closing price of €39.25. Stock is down 37% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €1.07 last year. Reported Earnings • Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: €1.08 (down from €2.41 in FY 2022). Revenue: €261.9m (down 4.6% from FY 2022). Net income: €13.1m (down 55% from FY 2022). Profit margin: 5.0% (down from 11% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 30% per year. Declared Dividend • Mar 24
Dividend of €0.55 announced Shareholders will receive a dividend of €0.55. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.3%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (98% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 8.9% to bring the payout ratio under control. EPS is expected to grow by 102% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Price Target Changed • Dec 18
Price target decreased by 8.5% to €52.17 Down from €57.00, the current price target is an average from 6 analysts. New target price is 28% above last closing price of €40.80. Stock is down 48% over the past year. The company is forecast to post earnings per share of €1.50 for next year compared to €2.41 last year. Duyuru • Nov 29
Stratec SE to Report Fiscal Year 2023 Results on Mar 21, 2024 Stratec SE announced that they will report fiscal year 2023 results on Mar 21, 2024 Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €46.30, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €56.48 per share. New Risk • Oct 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 98% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin). Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: €0.42 (vs €1.00 in 3Q 2022) Third quarter 2023 results: EPS: €0.42 (down from €1.00 in 3Q 2022). Revenue: €62.7m (down 11% from 3Q 2022). Net income: €5.11m (down 58% from 3Q 2022). Profit margin: 8.2% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Buying Opportunity • Oct 13
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be €54.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.4% over the last 3 years. Earnings per share has declined by 6.5%. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 21% per annum over the same time period. New Risk • Aug 10
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Aug 10
Second quarter 2023 earnings released: EPS: €0.086 (vs €0.12 in 2Q 2022) Second quarter 2023 results: EPS: €0.086 (down from €0.12 in 2Q 2022). Revenue: €64.5m (up 4.4% from 2Q 2022). Net income: €1.05m (down 27% from 2Q 2022). Profit margin: 1.6% (down from 2.3% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €49.50, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €86.13 per share. Price Target Changed • Jul 20
Price target decreased by 19% to €60.67 Down from €74.67, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €51.80. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.84 for next year compared to €2.41 last year. Duyuru • Jun 09
Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million. Stratec SE (XTRA:SBS) signed an agreement to acquire Natech Plastics, Inc. for $30 million on June 7, 2023. The transaction price agreed for the company, which has almost no debt, amounts to $30.0 million, plus a variable component (earn-out) based on defined performance criteria through to 2025. The transaction will be financed with a newly arranged credit line. In the 2022 financial year, its sales amounted to $16.3 million. The completion of the transaction, and thus first-time consolidation, are expected in July 2023. Upcoming Dividend • May 11
Upcoming dividend of €0.97 per share at 1.6% yield Eligible shareholders must have bought the stock before 18 May 2023. Payment date: 22 May 2023. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (1.6%). Price Target Changed • Apr 14
Price target decreased by 7.2% to €72.83 Down from €78.50, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €62.00. Stock is down 45% over the past year. The company is forecast to post earnings per share of €2.30 for next year compared to €2.41 last year. Reported Earnings • Apr 02
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: €2.41 (down from €3.30 in FY 2021). Revenue: €274.6m (down 4.4% from FY 2021). Net income: €29.2m (down 27% from FY 2021). Profit margin: 11% (down from 14% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 13
Price target decreased by 15% to €80.17 Down from €94.00, the current price target is an average from 6 analysts. New target price is 17% above last closing price of €68.50. Stock is down 35% over the past year. The company is forecast to post earnings per share of €2.68 for next year compared to €3.30 last year. Price Target Changed • Mar 03
Price target decreased by 9.5% to €94.00 Down from €104, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €76.20. Stock is down 29% over the past year. The company is forecast to post earnings per share of €2.77 for next year compared to €3.30 last year. Buying Opportunity • Nov 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 10%. The fair value is estimated to be €104, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.8% per annum. Earnings is also forecast to grow by 16% per annum over the same time period. Price Target Changed • Aug 25
Price target decreased to €102 Down from €114, the current price target is an average from 6 analysts. New target price is 18% above last closing price of €86.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: €0.12 (vs €1.13 in 2Q 2021) Second quarter 2022 results: EPS: €0.12 (down from €1.13 in 2Q 2021). Revenue: €61.8m (down 26% from 2Q 2021). Net income: €1.43m (down 90% from 2Q 2021). Profit margin: 2.3% (down from 16% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 12%, compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Price Target Changed • Aug 09
Price target decreased to €112 Down from €121, the current price target is an average from 5 analysts. New target price is 25% above last closing price of €89.40. Stock is down 33% over the past year. The company is forecast to post earnings per share of €3.04 for next year compared to €3.30 last year. Price Target Changed • Jul 26
Price target decreased to €114 Down from €125, the current price target is an average from 5 analysts. New target price is 19% above last closing price of €96.20. Stock is down 22% over the past year. The company is forecast to post earnings per share of €3.16 for next year compared to €3.30 last year. Upcoming Dividend • May 16
Upcoming dividend of €0.95 per share Eligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.3%). Lower than average of industry peers (1.2%). Reported Earnings • May 06
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: EPS: €0.92 (down from €0.95 in 1Q 2021). Revenue: €75.4m (up 4.7% from 1Q 2021). Net income: €11.2m (down 3.3% from 1Q 2021). Profit margin: 15% (down from 16% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.5%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 23% share price gain to €125, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 38x in the Medical Equipment industry in Germany. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €139 per share. Price Target Changed • Apr 06
Price target decreased to €126 Down from €138, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €126. Stock is up 8.6% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €3.30 last year. Buying Opportunity • Apr 01
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 25%. The fair value is estimated to be €135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 50%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings is also forecast to grow by 10% per annum over the same time period. Reported Earnings • Mar 31
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €3.30 (up from €2.36 in FY 2020). Revenue: €287.3m (up 15% from FY 2020). Net income: €40.0m (up 41% from FY 2020). Profit margin: 14% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 6.4%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €104, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 31x in the Medical Equipment industry in Germany. Total returns to shareholders of 80% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €111 per share. Reported Earnings • Nov 14
Third quarter 2021 earnings released: EPS €0.92 (vs €0.54 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €69.7m (up 17% from 3Q 2020). Net income: €11.2m (up 73% from 3Q 2020). Profit margin: 16% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 13
Price target increased to €147 Up from €132, the current price target is an average from 4 analysts. New target price is 14% above last closing price of €129. Stock is up 18% over the past year. The company is forecast to post earnings per share of €3.41 for next year compared to €2.36 last year. Reported Earnings • Aug 08
Second quarter 2021 earnings released: EPS €1.13 (vs €0.64 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €83.8m (up 33% from 2Q 2020). Net income: €13.6m (up 78% from 2Q 2020). Profit margin: 16% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Duyuru • May 21
Stratec SE Approves Dividend for the Year 2020, Payable on May 26, 2021 STRATEC SE at its Annual General Meeting held on May 20, 2021, approved to distribute a dividend of €0.90 per share to its shareholders for the past 2020 financial year (previous year: €0.84). The distribution total amounts to €10.9 million and will be paid out to shareholders through their depositing banks on May 26, 2021. This represents the seventeenth consecutive increase in the dividend since payment of the first dividend in 2004. Upcoming Dividend • May 14
Upcoming dividend of €0.90 per share Eligible shareholders must have bought the stock before 21 May 2021. Payment date: 26 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.1%). Duyuru • May 08
Stratec SE Confirms Earnings Guidance for the Year 2021 Stratec SE confirmed earnings guidance for the year 2021. For the 2021 financial year, STRATEC expects constant-currency sales growth at least in a high single-digit percentage range. Reported Earnings • May 08
First quarter 2021 earnings released: EPS €0.95 (vs €0.37 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €72.0m (up 27% from 1Q 2020). Net income: €11.5m (up 157% from 1Q 2020). Profit margin: 16% (up from 8.0% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Duyuru • Apr 28
Stratec SE Provides Sales Guidance for the First Quarter of Fiscal Year 2021 Stratec SE provided sales guidance for the first quarter of fiscal year 2021. For the quarter, the company expects consolidated sales of EUR 72.0 million. Reported Earnings • Apr 02
Full year 2020 earnings released: EPS €2.36 (vs €1.34 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €250.1m (up 13% from FY 2019). Net income: €28.4m (up 77% from FY 2019). Profit margin: 11% (up from 7.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 08
New 90-day low: €108 The company is down 9.0% from its price of €119 on 08 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.44 per share. Is New 90 Day High Low • Jan 23
New 90-day high: €135 The company is up 11% from its price of €122 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €98.43 per share. Price Target Changed • Jan 05
Price target raised to €129 Up from €119, the current price target is an average from 4 analysts. The new target price is close to the current share price of €123. As of last close, the stock is up 92% over the past year. Duyuru • Dec 23
Stratec SE, Annual General Meeting, May 20, 2021 Stratec SE, Annual General Meeting, May 20, 2021. Duyuru • Nov 27
Stratec SE Names Stefanie Remmele as New Chairwoman of the Supervisory Board At its meeting held on November 26, the Supervisory Board of STRATEC SE elected Prof. Dr. Stefanie Remmele as the new Chairwoman of the Supervisory Board as of November 26, 2020. Prof. Dr. Remmele is Professor of Medical Technology at Landshut University of Applied Sciences and has been a member of the Supervisory Board at STRATEC SE since 2014. Prof. Dr. Stefanie Remmele will succeed the previous Chair, Dr. Frank Hiller. Given the recommendations made in the new version of the German Corporate Governance Code, Dr. Hiller, who is CEO of DEUTZ AG, Cologne, will in future be Deputy Chair of the Supervisory Board. The management would like to thank Dr. Hiller for his great commitment to the STRATEC Group in his role as Chairman of the Supervisory Board. Valuation Update With 7 Day Price Move • Nov 12
Market pulls back on stock over the past week After last week's 18% share price decline to €108, the stock is trading at a trailing P/E ratio of 49.5x, down from the previous P/E ratio of 60.4x. This compares to an average P/E of 50x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 75%. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue and earnings miss expectations Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) also missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 14%, compared to a 13% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS €0.54 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €59.7m (up 18% from 3Q 2019). Net income: €6.48m (up 116% from 3Q 2019). Profit margin: 11% (up from 5.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 12
New 90-day high: €130 The company is up 41% from its price of €92.40 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €67.50 per share. 
